59660-95-6

Usage

Color

Colorless

Odor

Pungent

Solubility

Soluble in water and organic solvents

Specific content

It is a hydrochloride salt derived from 2-amino-2-methylpropanoyl chloride
Widely used as an intermediate in the synthesis of pharmaceuticals and other organic compounds
Primary use in the production of various drugs in the pharmaceutical industry
Also used as a reagent in organic synthesis and chemical research

Upstream product

• 62-57-7 2-Aminoisobutyric acid 
• 2491-06-7 N,N-dimethylglycine hydrochoride 
• 5938-34-1 2-amino-2-methyl-propanoic acid hydrochloride 

Downstream Products

• 491585-34-3 (E)-3-[4-(2-amino-2-methyl-propanoylamino)-phenyl]-acrylic acid ethyl ester 
• 1205602-91-0 {1-[1-chloro-4-(4-fluoro-phenyl)-isoquinolin-3-ylcarbamoyl]-1-methyl-ethyl}-amide 
• 934526-89-3 N-(3-{[(2Z)-3-[(2-chloro-5-methoxyphenyl)amino]quinoxalin-2(1H)-ylidene]sulfamoyl}phenyl)-2-methylalaninamide 
• 1205598-10-2 N-(2-Benzyl-5-phenyl-2H-pyrazol-3-yl)-2-[3-(2-chloro-phenyl)-ureido]-2-methyl-propionamide 
• 136928-41-1 2-(4-chlorophenyl)-4-(dimethylamino)acetyl-3,4-dihydro-2H-1,4-benzothiazine hydrochloride 

Relevant academic research and scientific papers

From benzimidazole to indole-5-carboxamide Thumb Pocket I inhibitors of HCV NS5B polymerase. Part 1: Indole C-2 SAR and discovery of diamide derivatives with nanomolar potency in cell-based subgenomic replicons

Replacement of the benzimidazole core of allosteric Thumb Pocket 1 HCV NS5B finger loop inhibitors by more lipophilic indole derivatives provided up to 30-fold potency improvements in cell-based subgenomic replicon assays. Optimization of C-2 substitution on the indole core led to the identification of analogs with EC50 100 nM and modulated the pharmacokinetic properties of the inhibitors based on preliminary data from in vitro ADME profiles and in vivo rat PK.

Copper-Promoted Thiolation of C(sp2)–H Bonds Using a 2-Amino Alkylbenzimidazole Directing Group

A copper-promoted thiolation of C(sp2)–H bonds with disulfides was achieved by using 2-amino alkylbenzimidazole (MBIP amine) as a new and removable N,N-bidentate directing group. This strategy gives a variety of functionalized thioethers in moderate to excellent yields in a simple and efficient way. Importantly, the substrate scope is not limited to aromatic amides; diverse alkenyl amides are also compatible. Furthermore, this synthetic approach provides a potentially feasible way to achieve structural modification of related benzimidazole-containing compounds through direct C–H activation.

Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies

Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compound A as described herein.

CRYSTALLINE COMPOUNDS

Provided herein are polymorph E, a mixed DMAC/toluene solvate and a DMSO solvate of N-(3-{[(2Z)-3-[(2-chloro-5- methoxyphenyl)amino]quinoxalin-2(1H)-ylidene]sulfamoyl}phenyl)-2- methylalaninamide.

TABLET FORMULATION OF A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR

Methods are provided for treating cancer to a patient in need of such treatment, comprising administering a PI3K inhibitor.

COMPOUNDS FOR USE IN THE TREATMENT OF BASAL CELL CARCINOMA

The invention provides a method for treating BCC in a patient in need of such treatment, comprising administering a therapeutically effective amount a compound of formula Ila.

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS FOR THE TREATMENT OF CANCER

The invention provides a method for treating endometrial carcinoma comprising administering a Compound of Formula (I) or (II). Also provided is a method for treating breast cancer, comprising administering letrozole in combination with either a Compound o

PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS FOR THE TREATMENT OF CHILDHOOD CANCERS

The invention provides a method for treating childhood cancers, including acute lymphocytic leukemia, neuroblastoma, and rhabdomyosarcoma, comprising administering a compound of Formula (I) to a patient in need of such treatment.

N- (3- { [ (3- { [2-CHLORO-5- (METHOXY) PHENYL] AMINO} QUINOXALIN- 2 -YL) AMINO] SULFONYL} PHE NYL) - 2 -METHYLALANINAMIDE AS PHOSPHATIDYLINOSITOL 3 - KINASE INHIBITOR FOR THE TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANCIES

Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compoud A as described herein.

Discovery of the first thumb pocket 1 NS5B polymerase inhibitor (BILB 1941) with demonstrated antiviral activity in patients chronically infected with genotype 1 hepatitis C virus (HCV)

Combinations of direct acting antivirals (DAAs) that have the potential to suppress emergence of resistant virus and that can be used in interferon-sparing regimens represent a preferred option for the treatment of chronic HCV infection. We have discovered allosteric (thumb pocket 1) non-nucleoside inhibitors of HCV NS5B polymerase that inhibit replication in replicon systems. Herein, we report the late-stage optimization of indole-based inhibitors, which began with the identification of a metabolic liability common to many previously reported inhibitors in this series. By use of parallel synthesis techniques, a sparse matrix of inhibitors was generated that provided a collection of inhibitors satisfying potency criteria and displaying improved in vitro ADME profiles. "Cassette" screening for oral absorption in rat provided a short list of potential development candidates. Further evaluation led to the discovery of the first thumb pocket 1 NS5B inhibitor (BILB 1941) that demonstrated antiviral activity in patients chronically infected with genotype 1 HCV.